JP2016523977A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523977A5
JP2016523977A5 JP2016525491A JP2016525491A JP2016523977A5 JP 2016523977 A5 JP2016523977 A5 JP 2016523977A5 JP 2016525491 A JP2016525491 A JP 2016525491A JP 2016525491 A JP2016525491 A JP 2016525491A JP 2016523977 A5 JP2016523977 A5 JP 2016523977A5
Authority
JP
Japan
Prior art keywords
phenyl
pyridin
ring
fluorophenyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016525491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523977A (ja
JP6471155B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/046204 external-priority patent/WO2015006592A1/en
Publication of JP2016523977A publication Critical patent/JP2016523977A/ja
Publication of JP2016523977A5 publication Critical patent/JP2016523977A5/ja
Application granted granted Critical
Publication of JP6471155B2 publication Critical patent/JP6471155B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016525491A 2013-07-11 2014-07-10 癌の治療のためのidh2変異体阻害剤としてのn,6−ビス(アリール又はヘテロアリール)−1,3,5−トリアジン−2,4−ジアミン化合物 Active JP6471155B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845352P 2013-07-11 2013-07-11
US61/845,352 2013-07-11
PCT/US2014/046204 WO2015006592A1 (en) 2013-07-11 2014-07-10 N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2016523977A JP2016523977A (ja) 2016-08-12
JP2016523977A5 true JP2016523977A5 (show.php) 2017-01-19
JP6471155B2 JP6471155B2 (ja) 2019-02-13

Family

ID=51261261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525491A Active JP6471155B2 (ja) 2013-07-11 2014-07-10 癌の治療のためのidh2変異体阻害剤としてのn,6−ビス(アリール又はヘテロアリール)−1,3,5−トリアジン−2,4−ジアミン化合物

Country Status (24)

Country Link
US (2) US9724350B2 (show.php)
EP (1) EP3019490B1 (show.php)
JP (1) JP6471155B2 (show.php)
KR (1) KR102302091B1 (show.php)
CN (1) CN105492435B (show.php)
AU (1) AU2014287122B9 (show.php)
BR (1) BR112016000489A8 (show.php)
CA (1) CA2917592A1 (show.php)
CL (1) CL2016000045A1 (show.php)
CR (1) CR20160022A (show.php)
EA (1) EA032070B1 (show.php)
ES (1) ES2807582T3 (show.php)
IL (1) IL243522B (show.php)
MX (1) MX375030B (show.php)
MY (1) MY185687A (show.php)
NI (1) NI201600007A (show.php)
NZ (1) NZ715738A (show.php)
PE (1) PE20160744A1 (show.php)
PH (1) PH12016500055A1 (show.php)
SA (1) SA516370386B1 (show.php)
SG (1) SG11201600058XA (show.php)
UA (1) UA119242C2 (show.php)
WO (1) WO2015006592A1 (show.php)
ZA (1) ZA201600210B (show.php)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ715738A (en) * 2013-07-11 2021-06-25 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN110372670B (zh) 2013-08-02 2023-04-07 法国施维雅药厂 治疗活性化合物及其使用方法
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3331866B1 (en) 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine
EP4147692A1 (en) 2015-10-15 2023-03-15 Les Laboratoires Servier Combination therapy for treating malignancies
KR102701893B1 (ko) * 2015-10-15 2024-09-03 셀진 코포레이션 악성종양을 치료하기 위한 조합 요법
AU2016363011B2 (en) 2015-12-04 2022-07-14 Les Laboratoires Servier Methods of treatment of malignancies
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
JP6856657B2 (ja) 2016-02-26 2021-04-07 アジオス ファーマシューティカルズ, インコーポレイテッド 血液学的悪性疾患および固形腫瘍の処置のためのidh1阻害剤
CN107382840B (zh) * 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
CN107556366B (zh) * 2016-06-30 2025-02-07 上海海和药物研究开发股份有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
CA3029343C (en) * 2016-07-21 2021-02-09 Nanjing Sanhome Pharmaceutical Co., Ltd. Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof
US20180042930A1 (en) 2016-08-03 2018-02-15 Celgene Corporation Methods of treatment of malignancies
AU2017324844B2 (en) 2016-09-07 2023-05-11 Celgene Corporation Tablet compositions
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
DK3644999T3 (da) 2017-06-30 2023-03-06 Celgene Corp Sammensætninger og fremgangsmåder til anvendelse af 2-(4-chlorphenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoracetamid
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药(上海)有限公司 环烯烃取代的杂芳环类化合物及其用途
CN110054617A (zh) * 2018-01-19 2019-07-26 南京圣和药业股份有限公司 三嗪类化合物、其制备方法及用途
US12215094B2 (en) 2018-11-02 2025-02-04 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
CN111662242B (zh) * 2019-03-08 2023-10-24 中国药科大学 杂环类idh突变体抑制剂、其制备方法及用途
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途
CN112250639B (zh) * 2020-11-19 2022-05-24 浙江工业大学 一种杂环取代的芳胺类化合物及其制备方法和应用
CN112592958B (zh) * 2020-12-07 2022-11-01 山东大学第二医院 利用fad依赖型d-2-羟基戊二酸脱氢酶和刃天青检测d-2-羟基戊二酸的方法
CN112645893A (zh) * 2020-12-28 2021-04-13 营口昌成新材料科技有限公司 一种二卤代均三嗪的合成方法
CN115536637B (zh) * 2022-10-24 2025-03-18 陕西中医药大学 一种均三嗪类衍生物及其合成方法与用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) * 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3867383A (en) 1971-03-29 1975-02-18 Ciba Geigy Corp Monoanthranilatoanilino-s-triazines
JPS5011392B2 (show.php) * 1971-08-07 1975-04-30
CH606334A5 (show.php) 1974-06-21 1978-10-31 Ciba Geigy Ag
JPS58186682A (ja) * 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
AU665238B2 (en) 1992-02-28 1995-12-21 Zenyaku Kogyo Kabushiki Kaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
CA2271744A1 (en) 1996-11-14 1998-05-22 Isao Hashiba Cyanoethylmelamine derivatives and process for producing the same
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンa3拮抗剤
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
AU5379900A (en) 1999-06-07 2000-12-28 Shire Biochem Inc. Thiophene integrin inhibitors
EP1397142A4 (en) 2001-06-19 2004-11-03 Bristol Myers Squibb Co PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
DK1423371T3 (da) 2001-08-17 2011-02-07 Basf Se Triazinderivater og anvendelse deraf som solbeskyttelse
JP4753336B2 (ja) 2001-09-04 2011-08-24 日本化薬株式会社 新規アリル化合物及びその製法
US7291616B2 (en) * 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
US6878196B2 (en) 2002-01-15 2005-04-12 Fuji Photo Film Co., Ltd. Ink, ink jet recording method and azo compound
US7205298B2 (en) * 2002-07-18 2007-04-17 Janssen Pharmaceutica N.V. Substituted triazine kinase inhibitors
JP2004107220A (ja) 2002-09-13 2004-04-08 Mitsubishi Pharma Corp TNF−α産生抑制剤
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US7361691B2 (en) 2002-12-02 2008-04-22 Arqule, Inc. Method of treating cancers using β-lapachone or analogs or derivatives thereof
JP4739763B2 (ja) 2002-12-16 2011-08-03 ゲンマブ エー/エス インターロイキン8(il−8)に対するヒトモノクローナル抗体
WO2005035507A2 (en) 2003-10-10 2005-04-21 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
WO2005065691A1 (en) 2003-12-24 2005-07-21 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
EP1796673A2 (en) 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
AU2006208834A1 (en) 2005-01-25 2006-08-03 Astrazeneca Ab Chemical compounds
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
US20100234341A1 (en) 2006-12-04 2010-09-16 Marion Lanier Substituted pyrimidines as adenosine receptor antagonists
ES2699585T3 (es) 2006-12-15 2019-02-11 Nantbio Inc Derivados de triazina y sus aplicaciones terapéuticas
CN101679321B (zh) 2007-04-30 2012-10-03 普罗米蒂克生物科学公司 三嗪衍生物、含所述衍生物的组合物以及所述衍生物在制备用于治疗癌症和自身免疫性疾病药物中的应用
WO2008154026A1 (en) 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
CN101981010A (zh) 2007-10-10 2011-02-23 武田药品工业株式会社 酰胺化合物
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5277685B2 (ja) 2008-03-26 2013-08-28 富士ゼロックス株式会社 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
CN101575408B (zh) 2008-05-09 2013-10-30 Mca技术有限公司 用作阻燃剂和光稳定剂的聚三嗪基化合物
US20100144722A1 (en) 2008-09-03 2010-06-10 Dr. Reddy's Laboratories Ltd. Novel heterocyclic compounds as gata modulators
JP2010079130A (ja) 2008-09-29 2010-04-08 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
JP2010181540A (ja) 2009-02-04 2010-08-19 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
BRPI1008661B8 (pt) 2009-02-06 2021-05-25 Nippon Shinyaku Co Ltd compostos derivados de aminopirazina, seu uso e composição farmacêutica
EP2406389B1 (en) 2009-03-13 2019-05-08 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
AU2010259002B2 (en) 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
KR20120026611A (ko) 2009-06-09 2012-03-19 아브락시스 바이오사이언스, 엘엘씨 헷지호그 신호전달의 피리딜-트리아진 억제제
JP2012529527A (ja) * 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ウレイドフェニル置換トリアジン誘導体類及びそれらの治療応用
WO2011005209A1 (en) 2009-07-10 2011-01-13 Milux Holding S.A. Knee joint device and method
JP5473851B2 (ja) 2009-09-30 2014-04-16 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011072174A1 (en) 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2011123618A1 (en) 2010-04-01 2011-10-06 Agios Pharmaceuticals, Inc. Methods of identifying a candidate compound
CA2805669C (en) 2010-07-16 2018-08-21 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US9351972B2 (en) 2010-11-29 2016-05-31 Galleon Pharmaceuticals, Inc. Compounds as respiratory stimulants for treatment of breathing control disorders or diseases
EP2691391A4 (en) 2011-03-29 2014-09-10 Broad Inst Inc COMPOUNDS AND METHODS OF TREATING DISORDERS MEDIATED BY ISOCITRATE DEHYDROGENASE
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102659765B (zh) 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
CN108912066B (zh) 2012-01-06 2022-06-24 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
EP2804850B1 (en) 2012-01-19 2018-08-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JPWO2013133367A1 (ja) 2012-03-09 2015-07-30 カルナバイオサイエンス株式会社 新規トリアジン誘導体
NZ715738A (en) * 2013-07-11 2021-06-25 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use

Similar Documents

Publication Publication Date Title
JP2016523977A5 (show.php)
ES2675760T3 (es) Compuestos terapéuticamente activos y métodos de uso de los mismos
RU2015100942A (ru) Производное пиперидинилпиразолпиридина
JP2015503571A5 (show.php)
JP2017075193A5 (show.php)
RU2015132181A (ru) Фтор-[1,3]-оксазины в качестве ингибиторов васе1
RU2012105284A (ru) Спиро-аминосоединения, пригодные для лечения нарушений сна и лекарственного привыкания
RU2018138050A (ru) Производные тиазолопиридина как агонисты gpr119
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
HRP20251479T1 (hr) Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi
RU2018138047A (ru) Гетероциклические вещества - агонисты gpr119
JP2017511329A5 (show.php)
JP2016525075A5 (show.php)
JP2016523935A5 (show.php)
RU2016111659A (ru) Соединение с агонистической активностью в отношении рецепторов соматостатина и его фармацевтическое применение
JP2019512482A5 (show.php)
RU2012126989A (ru) 2-амино-5,5-дифтор-5,6-дигидро-4н-оксазины в качестве ингибиторов васе 1 и(или) васе 2
JP2012525395A5 (show.php)
JP2016522231A5 (show.php)
JP2017500364A5 (show.php)
JP2016523976A5 (show.php)
JP2008519765A5 (show.php)
JP2011503230A5 (show.php)
JP2018508553A5 (show.php)
JP2015526452A5 (show.php)